Cargando…

SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells

MET-amplified gastric cancer cells are extremely sensitive to MET inhibition in vitro, whereas clinical efficacy of MET inhibitors is disappointing. The compensatory activation of other oncogenic growth factor receptors may serve as an underlying mechanism of resistance. In this study, we analyzed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jenke, Robert, Holzhäuser-Rein, Miriam, Mueller-Wilke, Stefanie, Lordick, Florian, Aigner, Achim, Büch, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796274/ https://www.ncbi.nlm.nih.gov/pubmed/33374770 http://dx.doi.org/10.3390/ijms22010082

Ejemplares similares

Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy
por: Gutsch, Daniela, et al.
Publicado: (2021)

SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC)
por: Panchal, Omkar, et al.
Publicado: (2020)

N(6)-methyladenine in DNA antagonizes SATB1 in early development
por: Li, Zheng, et al.
Publicado: (2020)

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
por: Jenke, Robert, et al.
Publicado: (2021)

Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells
por: Frömberg, Anja, et al.
Publicado: (2017)

Upregulation of SATB1 is associated with the development and progression of glioma
por: Chu, Sheng-Hua, et al.
Publicado: (2012)

Upregulation of SATB1 Is Associated with Prostate Cancer Aggressiveness and Disease Progression
por: Shukla, Sanjeev, et al.
Publicado: (2013)

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase
por: Yao, Hang-Ping, et al.
Publicado: (2021)

Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics
por: Liu, Xiangdong, et al.
Publicado: (2015)

The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth
por: Luraghi, Paolo, et al.
Publicado: (2012)

SATB1 plays an oncogenic role in esophageal cancer by up-regulation of FN1 and PDGFRB
por: Song, Guiqin, et al.
Publicado: (2017)

Hepatic SATB1 induces paracrine activation of hepatic stellate cells and is upregulated by HBx
por: Gong, Jin, et al.
Publicado: (2016)

The mRNA expression of SATB1 and SATB2 in human breast cancer
por: Patani, Neill, et al.
Publicado: (2009)

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
por: Kong, Anthony, et al.
Publicado: (2008)

Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma
por: Elebro, Jacob, et al.
Publicado: (2014)

Author Correction: Hepatic SATB1 induces paracrine activation of hepatic stellate cells and is upregulated by HBx
por: Gong, Jin, et al.
Publicado: (2021)

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
por: Liu, Y J, et al.
Publicado: (2014)

SATB1 and SATB2 play opposing roles in c-Myc expression and progression of colorectal cancer
por: Mansour, Mohammed A., et al.
Publicado: (2015)

Expression of SATB1 and SATB2 in the brain of bony fishes: what fish reveal about evolution
por: Lozano, Daniel, et al.
Publicado: (2023)

HER2, NF-κB, and SATB1 Expression Patterns in Gastric Cancer and Their Correlation with Clinical and Pathological Parameters
por: Smolińska, Marta, et al.
Publicado: (2019)

The histidine-rich calcium binding protein (HRC) promotes tumor metastasis in hepatocellular carcinoma and is upregulated by SATB1
por: Liu, Jingmei, et al.
Publicado: (2015)

Divergent expression patterns of SATB1 mRNA and SATB1 protein in colorectal cancer and normal tissues
por: Kowalczyk, Anna E., et al.
Publicado: (2015)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Activating mutation in MET oncogene in familial colorectal cancer
por: Neklason, Deborah W, et al.
Publicado: (2011)

Targeting MET Amplification as a New Oncogenic Driver
por: Kawakami, Hisato, et al.
Publicado: (2014)

An Observatory for the MET Oncogene: A Guide for Targeted Therapies
por: Altintas, Dogus M., et al.
Publicado: (2023)

Overcoming MET-mediated resistance in oncogene-driven NSCLC
por: Reischmann, Nadine, et al.
Publicado: (2023)

OTULIN Antagonizes LUBAC Signaling by Specifically Hydrolyzing Met1-Linked Polyubiquitin
por: Keusekotten, Kirstin, et al.
Publicado: (2013)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)

SATB1-mediated chromatin landscape in T cells
por: Zelenka, Tomas, et al.
Publicado: (2020)

The Role of SATB1 in Tumour Progression and Metastasis
por: Glatzel-Plucińska, Natalia, et al.
Publicado: (2019)

Satb2 is required for the regionalization of retrosplenial cortex
por: Zhang, Lei, et al.
Publicado: (2019)

Araguspongine C Induces Autophagic Death in Breast Cancer Cells through Suppression of c-Met and HER2 Receptor Tyrosine Kinase Signaling
por: Akl, Mohamed R., et al.
Publicado: (2015)

Role of Satb1 and Satb2 Transcription Factors in the Glutamate Receptors Expression and Ca(2+) Signaling in the Cortical Neurons In Vitro
por: Turovsky, Egor A., et al.
Publicado: (2021)

Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
por: Schäker‐Hübner, Linda, et al.
Publicado: (2022)

FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation
por: Park, Jinju, et al.
Publicado: (2018)

The Sno Oncogene Antagonizes Wingless Signaling during Wing Development in Drosophila
por: Quijano, Janine C., et al.
Publicado: (2010)

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
por: Wang, Jieyi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_68cbikr98i3rmd853r70um00do